As far as we are aware, this is the first study to evaluate Ang-2 and its receptors using both immunohistochemistry and qRT-PCR in primary ovarian cancer and related metastatic tumors from the same patients, and to correlate the expression data with the clinical outcome. Here, ANGPT2 is linked to ovarian carcinoma.